Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study that aims to evaluate the addition of MPDL3280A (atezolizumab) to carboplatin and
nab-paclitaxel in patients with early high-risk and locally advanced triple negative breast
cancer. compared to the control arm of carboplatin and abraxane. Half of participants will
receive MPDL3280A in combination with carboplatin and abraxane, while the other half will
receive only carboplatin and abraxane.